Novo Nordisk and AstraZeneca among firms to invest in Russian pharma hub
In Russia, the Kaluga government plans to establish a pharmaceutical manufacturing hub in the region that could net $1 billion of investment by local and international companies, Governor Anatoly Artamonov said this week, reports the Moscow Times.
The hub will start with six drugmakers - Denmark’s Novo Nordisk, Anglo-Swedish AstraZeneca, Germany’s Stada and Italy’s Menarini, as well as domestic drugmakers Nearmedic Plus and Sphera-Pharm - that already have a presence in the region, having jointly invested more than $500 million in their production facilities, Mr Artamonov said at a roundtable discussion about the prospects of the pharmaceutical industry.
The regional government is in talks with another four potential investors to join the hub. This could double existing investment by 2020, he said without specifying the companies because the negotiation process in still under way.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze